Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Int J Mol Sci. 2022 May 13;23(10):5466. doi: 10.3390/ijms23105466.
Engineered probiotics represent a cutting-edge therapy in intestinal inflammatory disease (IBD). Genetically modified bacteria have provided a new strategy to release therapeutically operative molecules in the intestine and have grown into promising new therapies for IBD. Current IBD treatments, such as corticosteroids and immunosuppressants, are associated with relevant side effects and a significant proportion of patients are dependent on these therapies, thus exposing them to the risk of relevant long-term side effects. Discovering new and effective therapeutic strategies is a worldwide goal in this research field and engineered probiotics could potentially provide a viable solution. This review aims at describing the proceeding of bacterial engineering and how genetically modified probiotics may represent a promising new biotechnological approach in IBD treatment.
工程益生菌代表了一种治疗肠道炎症性疾病（IBD）的前沿疗法。经过基因改造的细菌为在肠道中释放治疗性操作分子提供了一种新策略，并成为治疗 IBD 的有前途的新疗法。目前的 IBD 治疗方法，如皮质类固醇和免疫抑制剂，与相关的副作用有关，而且相当一部分患者依赖这些治疗方法，因此使他们面临相关的长期副作用的风险。在这个研究领域，发现新的和有效的治疗策略是全世界的目标，而工程益生菌可能为 IBD 治疗提供一种可行的解决方案。本综述旨在描述细菌工程的进展，以及遗传修饰的益生菌如何可能成为 IBD 治疗中一种有前途的新生物技术方法。
